Business
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress
Continues to advance preclinical discovery of its SCN9A research program, anticipates reporting results from initial in vivo animal studies by year-end 2022
About this update from Exicure, Inc.
[{"type":"text","content":"\n\nContinues to advance preclinical discovery of its SCN9A research program, anticipates reporting results from initial in vivo animal studies by year-end 2022\n\n\n\nContinues progression of work with partnered programs, with plan of meeting potential pre-clinical milestones in 2023\n\n\n CHICAGO--(BUSINESS WIRE)--\nExicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported full year financial results for the quarter and year ended December 31, 2021 and provided an update on its business strategy and corporate progress.\n\n“This past year brought significant challenges to our organization that prompted strategic decisions at year-end to refocus our business strategy on our next generation pipeline and investments in neuroscience in order to be cash efficient,” said Matthias Schroff, Ph.D., Chief Executive Officer of Exicure. “Entering 2022, I believe we are off to a good start as we have now fully aligned our resources to support development of our preclinical programs targeting SCN9A for the treatment of pain and advancement of ongoing discovery associated with our Ipsen and AbbVie partner programs. I want to acknowledge our team for their commitment to moving our company forward during this difficult time and thank them for their continued dedication in our mission to pursue treatments for patients with unmet medical needs,” concluded Dr. Schroff.\n\nCorporate Progress\n\nCorporate highlights for 2021 include:\n\n\nEntered into an exclusive collaboration targeting rare neurodegenerative disorders with Ipsen in July 2021 to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease (HD) and Angelman syndrome (AS).\n\n\n\nCompleted a strategic review in fourth quarter of 2021, which resulted in a restructuring and pipeline focus on preclinical programs targeting SCN9A in pain and partnered programs.\n\n\n\nCompleted a $11.5 million registered direct offering in December 2021.\n\n\nPriorities for 2022 include:\n\n\nAdvancement of the Company’s SCN9A preclinical discovery program. Exicure anticipates results from initial in vivo animal studies by year-end 2022 with goal of therapeutic candidate selection in the second half of 2023.\n\n\n\nProgressing work w...